NEW YORK (GenomeWeb News) – Investment research firm Morningstar has initiated a credit rating for Illumina of BB+, which it said reflects its negative view of the genetic analysis instrument business.
Morningstar said that although Illumina's financial position "looks solid," its rating "recognizes the fundamental advantages of competing in this industry." It also used Affymetrix's "recent downfall" in market position as a cautionary note for Illumina's creditors.